According to Fortune Business Insights, the global AI in real-world evidence market size was valued at USD 2.09 billion in 2025. The AI in real-world evidence market is projected to grow from USD 2.70 billion in 2026 to USD 21.00 billion by 2034, exhibiting a CAGR of 29.22% during the forecast period. North America dominated the AI in real-world evidence market with a 48.80% market share in 2025.
The AI in real-world evidence market is witnessing rapid expansion as healthcare organizations increasingly leverage artificial intelligence to generate actionable insights from real-world data collected through electronic health records, insurance claims, patient registries, wearable devices, and other healthcare sources. The growing emphasis on value-based healthcare, personalized medicine, and evidence-driven clinical decision-making is accelerating the adoption of AI-powered analytics across the pharmaceutical and biotechnology industries. AI technologies enable healthcare stakeholders to identify treatment patterns, evaluate patient outcomes, optimize clinical research, and support regulatory submissions with greater speed and accuracy. Pharmaceutical companies are increasingly integrating artificial intelligence into real-world evidence platforms to enhance drug development, post-market surveillance, and market access strategies. Continuous advancements in machine learning, natural language processing, predictive analytics, and cloud computing are improving the efficiency of data processing while supporting better healthcare outcomes. As healthcare systems continue to digitize and generate larger volumes of patient data, the AI in real-world evidence market is expected to experience substantial growth throughout the forecast period.
Continue reading for more details:
https://www.fortunebusinessinsights.com/ai-in-real-world-evidence-market-118102
The AI in real-world evidence market is segmented based on component, deployment mode, application, end user, and geography. By component, the market includes software, platforms, and services designed to collect, process, analyze, and interpret real-world healthcare data. Software solutions account for a significant share of the AI in real-world evidence market as healthcare organizations increasingly adopt AI-powered analytics platforms to improve evidence generation and clinical insights. Based on deployment mode, the market includes cloud-based and on-premise solutions, with cloud deployment gaining strong momentum due to its scalability, flexibility, and ability to process large healthcare datasets efficiently. By application, the AI in real-world evidence market covers drug development, pharmacovigilance, regulatory decision-making, clinical research, market access, reimbursement analysis, patient outcome monitoring, and precision medicine. Drug development and clinical research remain leading application areas as pharmaceutical companies seek to accelerate research timelines and improve clinical trial efficiency using real-world data. By end user, the market serves pharmaceutical companies, biotechnology companies, contract research organizations, healthcare providers, regulatory agencies, research institutions, and healthcare payers. Growing investments in artificial intelligence technologies and digital health infrastructure are expected to strengthen every segment of the AI in real-world evidence market over the coming years.
The AI in real-world evidence market is experiencing exceptional growth due to increasing adoption of artificial intelligence across the healthcare ecosystem and rising demand for data-driven clinical insights. Pharmaceutical and biotechnology companies are utilizing AI-powered real-world evidence platforms to improve clinical development, optimize patient recruitment, monitor treatment effectiveness, and accelerate regulatory approvals. The increasing availability of electronic health records, wearable health technologies, genomic databases, and healthcare claims data is providing vast amounts of information that can be analyzed using advanced AI algorithms. Machine learning and natural language processing technologies enable organizations to identify hidden clinical patterns, predict patient outcomes, and improve disease management strategies with greater efficiency. The AI in real-world evidence market is also benefiting from growing investments in digital transformation initiatives across hospitals, research institutions, and healthcare providers. Strategic collaborations between technology companies, pharmaceutical manufacturers, and healthcare organizations are accelerating innovation and expanding AI capabilities for evidence generation. Governments and regulatory agencies are increasingly recognizing the value of real-world evidence in supporting healthcare decision-making, encouraging broader adoption of AI-based analytical tools. Continuous advancements in cloud computing, big data analytics, and automation are further enhancing the scalability and accuracy of AI solutions. These developments are expected to drive sustained expansion of the AI in real-world evidence market through 2034.